-
公开(公告)号：US10030070B2
公开(公告)日：2018-07-24
申请号：US15694107
申请日：2017-09-01
Applicant: Janssen Biotech, Inc.
Inventor： Jacqueline Benson , Jill Carton , Mark Cunningham , Yevgeniya I. Orlovsky , Robert Rauchenberger , Raymond Sweet
Abstract: A human anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
-
公开(公告)号：US20150299330A1
公开(公告)日：2015-10-22
申请号：US14790144
申请日：2015-07-02
Applicant: JANSSEN BIOTECH, INC.
Inventor： John Chen , Johan Fransson , Natalie Fursov , Damon Hamel , Thomas Malia , Galina Obmolova , Tatiana Ort , Michael Rycyzyn , Michael Scully , Raymond Sweet , Alexey Teplyakov , John Wheeler , Juan Carlos Almagro
IPC: C07K16/28
CPC classification number: C07K16/2878 , A61K2039/505 , C07K16/2896 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
Abstract translation: 对人CD27免疫特异性的人抗体能够阻断CD27与其配体CD70结合并中和CD27的生物活性，包括但不限于CD27细胞内信号传导，T细胞增殖和活化，B细胞增殖和分化，浆细胞形成和缓解 的抗体反应，通过CD70刺激肿瘤细胞，以及从T和B细胞产生可溶性介质。 该抗体可用于诊断或治疗CD27活动相关疾病和病症。
-
公开(公告)号：US09096667B2
公开(公告)日：2015-08-04
申请号：US13968942
申请日：2013-08-16
Applicant: Janssen Biotech, Inc.
Inventor： Jacqueline Benson , Mark Cunningham , Cynthia Duchala , Jill M. Giles-Komar , Jinquan Luo , Michael A. Rycyzyn , Raymond Sweet
CPC classification number: A61K39/3955 , A61K39/00 , A61K45/06 , A61K2039/505 , A61K2039/55527 , A61K2039/55544 , C07K16/244 , C07K2317/30 , C07K2317/33 , C07K2317/34 , C07K2317/56 , C07K2317/565 , C07K2317/76 , C07K2317/92 , C07K2319/55 , G01N33/6869 , G01N2333/54 , Y02A50/386 , Y02A50/401 , Y02A50/41 , Y02A50/412 , Y02A50/55 , Y02A50/57 , Y02A50/58
Abstract: An anti-IL-23p19 antibody, including isolated nucleic acids that encode at least one anti-IL-23p19 antibody, vectors, host cells, transgenic animals or plants, and methods of making and using thereof have applications in diagnostic and/or therapeutic compositions, methods and devices.
-
公开(公告)号：US20130243795A1
公开(公告)日：2013-09-19
申请号：US13835518
申请日：2013-03-15
Applicant: JANSSEN BIOTECH, INC.
Inventor： John Chen , Johan Fransson , Natalie Fursov , Damon Hamel , Thomas Malia , Galina Obmolova , Tatiana Ort , Michael Rycyzyn , Michael Scully , Raymond Sweet , Alexey Teplyakov , John Wheeler , Juan Carlos Almagro
IPC: C07K16/28
CPC classification number: C07K16/2878 , A61K2039/505 , C07K16/2896 , C07K2317/24 , C07K2317/34 , C07K2317/55 , C07K2317/565 , C07K2317/73 , C07K2317/76 , C07K2317/92
Abstract: Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions.
Abstract translation: 对人CD27免疫特异性的人抗体能够阻断CD27与其配体CD70结合并中和CD27的生物活性，包括但不限于CD27细胞内信号传导，T细胞增殖和活化，B细胞增殖和分化，浆细胞形成和缓解 的抗体反应，通过CD70刺激肿瘤细胞，以及从T和B细胞产生可溶性介质。 该抗体可用于诊断或治疗CD27活动相关疾病和病症。
-
-
-
Search Results
44
records
(took 0.036 seconds)
